These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35105287)

  • 1. SARS-CoV-2 Infections, Impaired Tissue, and Metabolic Health: Pathophysiology and Potential Therapeutics.
    Singh SP; Bhatnagar A; Singh SK; Patra SK; Kanwar N; Kanwal A; Amar S; Manna R
    Mini Rev Med Chem; 2022; 22(16):2102-2123. PubMed ID: 35105287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
    Rico-Mesa JS; White A; Anderson AS
    Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
    Verdecchia P; Cavallini C; Spanevello A; Angeli F
    Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
    Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
    Elife; 2020 May; 9():. PubMed ID: 32452762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
    Hu Y; Liu L; Lu X
    Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
    Ingraham NE; Barakat AG; Reilkoff R; Bezdicek T; Schacker T; Chipman JG; Tignanelli CJ; Puskarich MA
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of COVID-19 pathogenesis in diabetes.
    Aluganti Narasimhulu C; Singla DK
    Am J Physiol Heart Circ Physiol; 2022 Sep; 323(3):H403-H420. PubMed ID: 35776683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.
    Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM
    J Drug Target; 2020; 28(7-8):683-699. PubMed ID: 32700580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
    Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
    Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Race for ACE: Targeting Angiotensin-Converting Enzymes (ACE) in SARS-CoV-2 Infection.
    Schieffer E; Schieffer B
    J Renin Angiotensin Aldosterone Syst; 2022; 2022():2549063. PubMed ID: 35685188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?
    Filardi T; Morano S
    J Endocrinol Invest; 2020 Aug; 43(8):1053-1060. PubMed ID: 32495299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
    Lores E; Wysocki J; Batlle D
    Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of ACE2 in COVID-19].
    Imai Y
    Nihon Yakurigaku Zasshi; 2022; 157(2):115-118. PubMed ID: 35228442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.
    Cure E; Cumhur Cure M
    Diabetes Metab Syndr; 2020; 14(4):349-350. PubMed ID: 32311651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
    Nicolau LAD; Magalhães PJC; Vale ML
    Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes.
    Obukhov AG; Stevens BR; Prasad R; Li Calzi S; Boulton ME; Raizada MK; Oudit GY; Grant MB
    Diabetes; 2020 Sep; 69(9):1875-1886. PubMed ID: 32669391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19.
    Haslbauer JD; Stalder A; Zinner C; Bassetti S; Mertz KD; Went P; Matter M; Tzankov A
    Pathobiology; 2022; 89(3):166-177. PubMed ID: 34915500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.